Muzaffargarh

Researchers are evaluating the effects of L-carnitine supplementation in preterm babies suffering from Respiratory Distress Syndrome (RDS). This study aims to clarify conflicting results about how L-carnitine affects short-term outcomes such as weight gain, discharge rates, and mortality in these infants. The research seeks to provide clear evidence on whether L-carnitine is a safe and useful addition to standard care for preterm neonates with RDS, especially in addressing their specific metabolic needs. The study involves two groups: one group will receive L-carnitine at a dose of 30 mg per kg per day alongside a standard care regimen, while the other group will receive only the standard care. The standard care consists of a total dose of 100 mg phospholipids per kg of birth weight, given in four divided doses. These treatments will be administered during the neonatal intensive care unit stay. Participants will be closely monitored for outcomes including mortality and changes in weight over 30 days. Evaluations will include clinical assessments in the NICU, with attention to safety and effectiveness of the supplementation. The total study duration for each participant covers at least the first 30 days of life, during which detailed observations and measurements will be collected to assess the impact of the treatments.